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About 180,000 new cases of urinary 
bladder cancer are diagnosed each year in 
the European Union. The most relevant risk 
factors are occupational exposure to aro-
matic amines and cigarette smoking (Golka 
et al., 2012; Ovsiannikov et al., 2012; 
Selinski et al., 2013; Kempkes et al., 1996). 
Recently, genome-wide association studies 
have successfully identified several urinary 
bladder cancer susceptibility loci (review: 
Dudek et al., 2013; Golka et al., 2011; 
Selinski, 2012; Bolt, 2013a, b). Currently 
confirmed genetic variants include 
rs9642880 (MYC, Kiemeney et al., 2008; 
Golka et al., 2009), rs710521 (TP63, 
Kiemeney et al., 2008; Lehmann et al., 
2010), rs401681 and rs2736098 
(CLPTM1L, TERT, Rafnar et al., 2009), 
rs2294008 and rs2978974 (PSCA, Wu et 
al., 2009; Fu et al., 2012), rs798766 
(TACC3, FGFR3, Kiemeney et al., 2010), 
rs11892031 (UGT1A, Rothman et al., 
2010; Selinski et al., 2012), rs17863783 
(UGT1A6, Tang et al., 2012), rs1495741 
(NAT2, Rothman et al., 2010; Garcia-
Closas et al., 2011; Selinski et al., 2011), 
rs8102137 (CCNE1, Rothman et al., 2010), 
rs1014971 (CBX6, Rothman et al., 2010) 
and rs17674580 and rs1058396 (SLC14A1, 
Rafnar et al., 2011). Moreover, it has been 
shown that several high risk alleles of sin-
gle nucleotide polymorphisms can interact 
leading to enhanced odds ratios (Schwender 
et al., 2012). However, relatively little is 
known about the functional consequences 
of the novel bladder cancer susceptibility 
SNPs. Many of them are located in non-
coding regions. An example is rs9642880 
on chromosome 8q24 that is approximately 
30kb upstream of MYC (Kiemeney et al., 
2008). Similarly, rs1014971 on 22q13.1 is 
located 25 kb and 64kb from APOBEC3A 
and CBX6, respectively (Rothman et al., 
2010). Considering these relatively large 
distances between both SNPs and the clos-
est exons it seems unlikely that an influence 
can be explained by linkage disequilibrium. 
Recently, Dudek and colleagues have ad-
dressed the open question of the functional 
consequences of urinary bladder suscepti-
bility loci (Dudek et al., 2013). At least two 
risk variants, located in PSCA and UGT1A, 
were confirmed to have functional conse-
quences. 
 PSCA (prostate stem cell antigen) is 
involved in the regulation of stem cell 
proliferation. Rs2294008 is located in 
the first exon of PSCA (review: Dudek 
et al., 2013). It changes a nucleotide in 
the initiation region, creates a new ATG 
for translation initiation leading to a 
PSCA protein which is nine amino acids 
longer (Dudek et al., 2013). Rs294008 
was found to be strongly associated 
with PSCA protein levels in urinary 
bladder tumors. Moreover, a second 
variant, rs2978974, was also identified 
in exon 1 of PSCA and was found to be 
associated with urinary bladder cancer 
risk (Fu et al., 2012; review: Dudek et 
al., 2013). 
 UDP-glucuronosyltransferase (UGT) is 
a phase II metabolizing enzyme in-
volved in detoxification of numerous 
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carcinogens (Burkhardt et al., 2012; 
Hanioka et al., 2011; Luo et al., 2012; 
Godoy et al., 2013). One bladder cancer 
susceptibility locus is located in intron 1 
of UGT, containing rs11892031 (Roth-
man et al., 2010; Dudek et al., 2013). 
Follow-up studies identified the causa-
tive variant rs17863783 (Tang et al. 
2012). Rs17863783 does not alter the 
amino acid sequence of UGT1A. How-
ever, a possible explanation is that 
rs17863783 modifies the expression of 
UGT1A by influencing the exonic splic-
ing enhancer, a DNA sequence motif 
essential for the identification of splice 
sites (Dudek et al., 2013).  
The current review article of Dudek et 
al. (2013) describes in a comprehensive 
way the current concepts by which mecha-
nisms the recently identified bladder cancer 
risk loci may contribute to carcinogenesis. 
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